Skip to main content

As public companies prepare for 2026 annual reporting and proxy season, Mintz highlights key developments from 2025 and considerations for year-end SEC filings. While the SEC did not adopt major new disclosure rules in 2025, the year marked a significant shift in regulatory priorities under the new administration. Numerous proposals were withdrawn, and attention turned to emerging financial technology, executive compensation, and principles-based disclosure standards. At the same time, state-level initiatives advanced independently, creating a patchwork of requirements that companies must navigate.

Looking ahead, issuers should anticipate continued policy volatility and uneven compliance obligations across jurisdictions. Diverging state and federal mandates, evolving guidance on AI and data practices, and sector-specific oversight in areas such as life sciences and fintech will heighten disclosure and governance risks. Boards and management teams should ensure that risk factors and MD&A sections are updated to address these developments, including cybersecurity, tariffs, geopolitical uncertainty, and the growing use of AI.

Other areas of focus include proxy advisory policy changes, digital asset regulation, and employment considerations. Life sciences companies face additional complexity as FDA operations adjust to leadership changes and new initiatives. Finally, recent litigation and Delaware corporate law reforms underscore the need for robust governance practices and careful disclosure planning.

Subscribe To Viewpoints

Authors

Anne L. Bruno is a Member at Mintz who advises clients ranging from start-ups to multinational public companies on issues related to corporate and employment law, including executive compensation, employee benefits, securities law, and corporate governance. She is also a key member of the firm’s multidisciplinary ESG practice, helping corporate boards, companies, and their investors navigate a broad range of environmental, social, and governance considerations.
Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Melanie Ruthrauff Levy is a Mintz attorney who counsels venture and private equity funds and public and private companies in corporate governance, public company reporting, and transactional matters. She represents issuers and financing sources in the life sciences, health care, and tech fields.
Page R. Hubben

Page R. Hubben

Special Counsel

Page R. Hubben is a Mintz attorney who advises public companies on capital-raising transactions, SEC reporting, and corporate governance. She also counsels public and private companies on a broad range of executive compensation and equity compensation arrangements and programs, including equity and incentive plans and related tax, corporate, and securities law concerns.
Joanne counsels global clients on the regulatory and distribution-related implications when bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized.
Jacob H. Hupart is Co-Chair of the ESG Practice Group and a Member in the firm’s Litigation Section. He has a multifaceted litigation practice that encompasses complex commercial litigation, securities litigation — including class action claims — as well as white collar criminal defense and regulatory investigations. His clients sit in a variety of industries, including energy, financial services, education, health care, and the media.
Breton Leone-Quick is an attorney who advises Mintz clients in the financial services industry in litigation matters and regulatory investigations. He leverages his understanding of federal securities laws and Delaware corporate laws to navigate complex crises and disputes.
Jennifer B. Rubin is a Mintz Member who advises clients on employment issues like wage and hour compliance. Her clients range from start-ups to Fortune 50 companies and business executives in the technology, financial services, publishing, professional services, and health care industries.
Benjamin advises pharmaceutical, medical device and biotech companies on the FDA regulatory process to identify the correct regulatory pathway, assisting with FDA communications and strategy.
Mintz attorney Nicole M. Rivers defends employers in employment litigation and labor matters and advises on employment best practices. She handles cases involving claims of wage and hour violations, harassment, retaliation, discrimination, breach of employment agreements, FMLA violations, and violations of California's Private Attorneys General Act (PAGA), Family Rights Act (CFRA), and Fair Employment and Housing Act (FEHA).